Two additional CDK4/6 inhibitors, LEE 001 from Novartis (Basel, Switzerland) and LY 2835219 from Eli Lilly (Indianapolis, IN, USA), are also under investigation for breast and other cancers.76 In October 2015, Lilly received Food Drug and Administration Breakthrough Therapy Designation for its CDK4/6 inhibitor, Abemaciclib.77 Here, CDK4 is linked to cancer.